Package Leaflet: Information for the User
Pirfenidone Tecnigen 267 mg film-coated tablets EFG
Pirfenidone Tecnigen 801 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
5 Conservation of Pirfenidone Tecnigen
Pirfenidone Tecnigen contains the active substance pirfenidone and is used for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in adults.
IPF is a disease in which the lung tissue becomes thickened and scarred over time, making it difficult to breathe deeply. In these circumstances, the lungs have difficulty functioning properly. Pirfenidone helps reduce scarring and swelling of the lungs, and helps you breathe better.
Do not take Pirfenidone Tecnigen
If any of the above applies to you, do not take pirfenidone. If you are in doubt, consult your doctor or pharmacist.
Warnings and precautions
Consult your doctor or pharmacist before starting to take pirfenidone.
Pirfenidone may cause serious liver problems. Some cases have been fatal. You will need to have a blood test before starting to take pirfenidone, once a month for the first 6 months, and then every 3 months while taking this medicine, to check your liver function. It is essential that you have these blood tests periodically throughout the time you are taking pirfenidone.
Children and adolescents
Do not give pirfenidone to children and adolescents under 18 years of age.
Other medicines and Pirfenidone Tecnigen
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
This is especially important if you are taking the following medicines, as they may alter the effect of pirfenidone.
The following medicines may increase the side effects of pirfenidone:
The following medicines may reduce the effectiveness of pirfenidone:
Taking Pirfenidone Tecnigen with food and drinks
Do not drink grapefruit juice while taking this medicine. Grapefruit juice may cause pirfenidone to not work properly.
Pregnancy and breast-feeding
As a precautionary measure, it is preferable to avoid the use of pirfenidone if you are pregnant, planning to become pregnant, or think you may be pregnant, as the potential risks to the fetus are not known.
If you are breast-feeding or planning to breast-feed, consult your doctor or pharmacist before taking pirfenidone. Since it is not known whether pirfenidone is excreted in breast milk, your doctor will explain the risks and benefits of taking this medicine during breast-feeding if you decide to do so.
Driving and using machines
Do not drive or operate machinery if you feel dizzy or tired after taking pirfenidone.
Pirfenidone Tecnigen contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, i.e., it is essentially "sodium-free".
Treatment with pirfenidone should be initiated and supervised by specialized doctors with experience in the diagnosis and treatment of IPF.
Follow the instructions for administration of this medicine indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Normally, you will be given this medicine by gradually increasing the dose as follows:
The recommended daily maintenance dose of pirfenidone is 801 mg three times a day with food, a total of 2,403 mg/day.
Swallow the tablets whole with water, during or after a meal to reduce the risk of side effects such as nausea and dizziness. If symptoms persist, consult your doctor.
Dose reduction due to side effects
It is possible that your doctor may decide to reduce the dose if you experience side effects such as stomach problems, skin reactions to sunlight or UVA lamps, or significant changes in liver enzymes.
If you take more Pirfenidone Tecnigen than you should
Go to your doctor, pharmacist, or the emergency department of the nearest hospital immediately if you take more tablets than you should, and take your medication with you.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take Pirfenidone Tecnigen
If you forget to take a dose, take it as soon as you remember. Do not take a double dose to make up for forgotten doses. Each dose should be separated by an interval of at least 3 hours. Do not take more tablets per day than your prescribed daily dose.
If you stop taking Pirfenidone Tecnigen
In certain situations, your doctor will advise you to stop taking pirfenidone. If for any reason you stop taking pirfenidone for more than 14 consecutive days, your doctor will restart your treatment with a dose of 267 mg 3 times a day and gradually increase it to 801 mg 3 times a day.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking pirfenidone and seek medical attention immediately if you notice any of the following symptoms or signs:
Other side effects may include:
If you experience any type of side effect, consult your doctor.
Very common side effects(may affect more than 1 in 10 people):
Common side effects(may affect up to 1 in 10 people):
Uncommon side effects(may affect up to 1 in 100 people):
Reporting of side effects
If you experience any side effects, consult your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Surveillance System for Human Use: http://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date that appears on the blister pack and carton after EXP. The expiry date is the last day of the month indicated.
Do not store above 30°C.
Medicines should not be disposed of via wastewater or household waste. Place the empty packaging and any unused medicinal products in the SIGRE collection point at your pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and unused medicines. This will help protect the environment.
Composition of Pirfenidone Tecnigen
Pirfenidone Tecnigen 267 mg film-coated tablets EFG
The active substance is pirfenidone. Each film-coated tablet contains 267 mg of pirfenidone.
The other ingredients are: microcrystalline cellulose, sodium croscarmellose (see section 2 "Pirfenidone Tecnigen contains sodium"), povidone, and magnesium stearate.
The film coating consists of: poly(vinyl alcohol), titanium dioxide (E171), macrogol 4000, talc, and yellow iron oxide (E172).
Pirfenidone Tecnigen 801 mg film-coated tablets EFG
The active substance is pirfenidone. Each film-coated tablet contains 801 mg of pirfenidone.
The other ingredients are: microcrystalline cellulose, sodium croscarmellose (see section 2 "Pirfenidone Tecnigen contains sodium"), povidone, and magnesium stearate.
The film coating consists of: poly(vinyl alcohol), titanium dioxide (E171), macrogol 4000, talc, red iron oxide (E172), black iron oxide (E172), and yellow iron oxide (E172).
Appearance and packaging
Pirfenidone Tecnigen 267 mg film-coated tablets EFG are yellow, oval-shaped film-coated tablets.
The blister pack contains 63 or 252 film-coated tablets.
Pirfenidone Tecnigen 801 mg film-coated tablets EFG are purple-brown, oval-shaped film-coated tablets.
The blister pack contains 84 film-coated tablets.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Farmoz Sociedade Técnico Medicinal, S.A.
Rua da Tapada Grande, nº 2, Abrunheira
2710-228 Sintra (Portugal)
Manufacturer
Tecnimede – Sociedade Técnico-Medicinal S.A.
Quinta da Cerca, Caixaria
2565-187 Dois Portos (Portugal)
You can request more information about this medicine by contacting the local representative of the marketing authorization holder
Local representative:
Tecnimede España Industria Farmacéutica, S.A.
Avda. Bruselas, 13. 3ºD. Polígono Arroyo de la Vega
28108 Alcobendas (Madrid) Spain
Date of the last revision of this leaflet:July 2024
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).